72
Participants
Start Date
April 8, 2025
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
iQ-007
Highly selective, orally bioavailable, positive allosteric modulator (PAM) of the excitatory amino acid transporter-2 (EAAT2) and its rodent homologue (glutamate transporter-1\[GLT-1).
Placebo
Oral capsules identical in appearance to drug and containing vehicle only (Gelucire/Capmul-M).
RECRUITING
CMAX Clinical Research Pty Ltd, Adelaide
Collaborators (1)
Avance Clinical Pty Ltd.
INDUSTRY
iQure Australia Pty Ltd
INDUSTRY